5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow acebilustat: new trials by email Literature Review of acebilustat trials Research Report on acebilustat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Placebo Controlled Trial of Acebilustat (CTX 4430) for the Treatment of Human Upper Extremity Lymphedema Acebilustat, Placebo - Lymphedema of Upper Arm | Phase 2 | Completed | Stanford University | 40 | 2022-07-27 | 2026-05-28 |
| COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol Acebilustat, Placebo - Covid19 | Phase 2 | Completed | Stanford University | 120 | 2021-04-23 | 2023-06-13 |
| COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol Acebilustat, Camostat - Covid19 | Phase 2 | Completed | Stanford University | 122 | 2021-04-23 | 2023-06-28 |
| EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients CTX-4430, Placebo - Cystic Fibrosis | Phase 2 | Completed | Celtaxsys, Inc. | 200 | 2015-10-30 | 2019-09-04 |
| CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris CTX-4430, Placebo - Acne Vulgaris | Phase 2 | Completed | Celtaxsys, Inc. | 124 | 2015-04-01 | 2016-08-02 |
COVID-19 (2) · Acne Vulgaris (1) · Cystic Fibrosis (1)
Stanford University (3) · Celtaxsys, Inc. (2)
United States (4) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Italy (1) · New Zealand (1) · United Kingdom (1)
Angela Rogers, MD (1) · Chaitan Khosla, PhD (1) · Haley Hedlin, PhD (1) · Joseph Levitt, MD, MS (1) · Lynda J Spelman, MB BS, FACD (1) · Manisha Desai, PhD (1) · Stanley Rockson, MD (1) · Steven Rowe, MD (1) · Stuart Elborn, MD (1) · Upinder Singh, MD (1) · Yvonne Maldonado, MD (1)